Rep. Diana DeGette (D-Colo.), co-chair of the Congressional Diabetes Caucus, unveiled a bipartisan bill yesterday that aims to reduce “skyrocketing” costs of insulin in the U.S. The legislation, which DeGette plans to introduce after the congressional recess, would provide insulin manufacturers an “incentive” to set the list price of their insulin at or below the price it was set at in 2006, according to a statement from DeGette. “That would cut the price of most insulin products on the market today by more than 75%,” according to the statement.